StockIQpro
NASDAQ:LGND

Ligand Pharmaceuticals Inc.

Track all markets on TradingView
Track all markets on TradingView

Ligand Pharmaceuticals Inc.'s revenue grew 60.4% in fiscal 2025 to $268.1M while operating margin rose to 15.3%. Free cash flow was $48.9M, 18.2% of revenue, and the diluted share count rose 11.0%.Summary generated from Ligand Pharmaceuticals Inc.'s SEC filings. Latest annual report filed Feb 27, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$268.1M
Revenue growth+60.4%
Revenue, 5-yr CAGR+10.4%
Gross marginn/a
Operating margin15.3%
Net margin46.4%
ROICn/a
Return on equity13.5%
Debt / equityn/a
Free cash flow$48.9M
FCF margin18.2%
Share count change+11.0%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue242196131167268
Operating income104312−2341
Net income57−3352−4124
Free cash flow70120469549

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations